Clinical Drug Investigation

, Volume 31, Issue 6, pp 407–415

Long-Term Renal Safety of Tenofovir Disoproxil Fumarate in Vertically HIV-Infected Children, Adolescents and Young Adults

A 60-Month Follow-Up Study
  • Alessandra Viganò
  • Giorgio Bedogni
  • Valeria Manfredini
  • Vania Giacomet
  • Chiara Cerini
  • Francesca di Nello
  • Francesca Penagini
  • Cristiana Caprio
  • Gian Vincenzo Zuccotti
Original Research Article


Background and Objective: Sporadic cases of renal toxicity have been reported in HIV-infected children treated with tenofovir disoproxil fumarate (TDF). We assessed the long-term renal safety of TDF in a cohort of vertically HIV-infected children, adolescents and young adults.

Methods: We evaluated 26 HIV-infected children, adolescents and young adults, aged 4.9–17.4 years at baseline, every 6 months for 60 consecutive months. At the baseline visit, they had an undetectable viral load and a good immune reconstitution and were being treated with lamivudine, stavudine and a protease inhibitor (PI). At the same visit, stavudine was replaced with TDF and the PI with efavirenz. Serum creatinine, estimated glomerular filtration rate (GFR), urine protein to creatinine ratio, serum phosphate, ratio of the maximum rate of tubular phosphate reabsorption to the GFR (TmPO4/GFR), urine glucose, and urine α1-microglobulin to creatinine ratio were used as markers of renal function. The outcome-time relationships were studied using generalized estimating equations (GEEs). In addition to time (continuous, ten equally spaced intervals), sex, age at baseline and CD4+ T-cell count were used as covariates.

Results: A moderate reduction in GFR was observed only once in an underweight female patient. There was no occurrence of proteinuria, hypophosphataemia or glycosuria. Moreover, TmPO4/GFR was stable and the urine α1-microglobulin to creatinine ratio was always within normal limits.

Conclusion: TDF had an excellent renal safety profile in HIV-infected children, adolescents and young adults regularly followed up for 60 months.


  1. 1.
    Boyd MA. Improvements in antiretroviral therapy outcomes over calendar time. Curr Opin HIV AIDS 2009 May; 4(3): 194–9PubMedCrossRefGoogle Scholar
  2. 2.
    Atta MG, Deray G, Lucas GM. Antiretroviral nephro-toxicities. Semin Nephrol 2008 Nov; 28(6): 563–75PubMedCrossRefGoogle Scholar
  3. 3.
    Rodriguez-Nóvoa S, Alvarez E, Labarga P, et al. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf 2010 Jul; 9(4): 545–59PubMedCrossRefGoogle Scholar
  4. 4.
    Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010 Sep 1; 51(5): 496–505PubMedCrossRefGoogle Scholar
  5. 5.
    Van Rompay KK, Brignolo LL, Meyer DJ, et al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 2004 May; 48(5): 1469–87PubMedCrossRefGoogle Scholar
  6. 6.
    Peyrière H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004; 35(3): 269–73PubMedCrossRefGoogle Scholar
  7. 7.
    Izzedine H, Isnard-Bagnis C, Hulot JS, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004; 18(7): 1074–6PubMedCrossRefGoogle Scholar
  8. 8.
    Parsonage MJ, Wilkins EG, Snowden N, et al. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med 2005; 6(5): 341–6PubMedCrossRefGoogle Scholar
  9. 9.
    Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatmentnaive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008; 47(1): 74–8PubMedCrossRefGoogle Scholar
  10. 10.
    Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292(2): 191–201PubMedCrossRefGoogle Scholar
  11. 11.
    Shooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002, Jun 14; 16(9): 1257–63CrossRefGoogle Scholar
  12. 12.
    Moyle GJ, Sabin CA, Cartledge J, et al., RAVE (Randomized Abacavir versus Viread Evaluation) Group UK. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20(16): 2043–50PubMedCrossRefGoogle Scholar
  13. 13.
    Martínez E, Arranz JA, Podzamczer D, et al. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr 2009; 51(3): 290–7PubMedCrossRefGoogle Scholar
  14. 14.
    Hazra R, Gafni RI, Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics 2005 Dec; 116(6): e846–54PubMedCrossRefGoogle Scholar
  15. 15.
    Viganò A, Zuccotti GV, Martelli L, et al. Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study. Clin Drug Investig 2007; 27(8): 573–81PubMedCrossRefGoogle Scholar
  16. 16.
    Soler-Palacín P, Melendo S, Noguera-Julian A, et al. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens. AIDS 2011; 25(2): 171–6PubMedCrossRefGoogle Scholar
  17. 17.
    Cacciari E, Milani S, Balsamo A, et al. Italian cross-sectional growth charts for height, weight and BMI (6–20 y). Eur J Clin Nutr 2002 Feb; 56(2): 171–80PubMedCrossRefGoogle Scholar
  18. 18.
    Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviralnaive HIV-1-infected patients: data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005 Apr; 20(4): 743–6PubMedCrossRefGoogle Scholar
  19. 19.
    Hogg RJ, Furth S, Lemley KV, et al. National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 2003 Jun; 111 (6 Pt 1): 1416–21PubMedCrossRefGoogle Scholar
  20. 20.
    Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009 Mar; 20(3): 629–37PubMedCrossRefGoogle Scholar
  21. 21.
    Division of AIDS. Division of AIDS table for grading the severity of adult and pediatric adverse events. Bethesda (MD): NIH, 2005Google Scholar
  22. 22.
    Alon U, Hellerstein S. Assessment and interpretation of the tubular threshold for phosphate in infants and children. Pediatr Nephrol 1994 Apr; 8(2): 250–1PubMedCrossRefGoogle Scholar
  23. 23.
    Hardin JW, Hilbe J. Generalized estimating equations. Boca Raton (FL): Chapman & Hall, 2003Google Scholar
  24. 24.
    Royston P, Sauerbrei W. Multivariable model-building: a pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables. Chichester: John Wiley, 2008Google Scholar
  25. 25.
    Viganò A, Brambilla P, Pattarino G, et al. Long-term evaluation of glucose homeostasis in a cohort of HAART-treated HIV-infected children: a longitudinal, observational cohort study. Clin Drug Investig 2009; 29(2): 101–9PubMedCrossRefGoogle Scholar
  26. 26.
    Kruse K, Kracht U, Göpfert G. Renal threshold phosphate concentration (TmPO4/GFR). Arch Dis Child 1982 Mar; 57(3): 217–23PubMedCrossRefGoogle Scholar
  27. 27.
    Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006 Jan 15; 42(2): 283–90PubMedCrossRefGoogle Scholar
  28. 28.
    Hawkins S, Ball C. Adverse events experienced by three children taking tenofovir and didanosine in combination. HIV Med 2007 Sep; 8(6): 411PubMedCrossRefGoogle Scholar
  29. 29.
    Hussain S, Khayat A, Tolaymat A, et al. Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. Pediatr Nephrol 2006 Jul; 21(7): 1034–6PubMedCrossRefGoogle Scholar
  30. 30.
    Andiman WA, Chernoff MC, Mitchell C, et al. Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. Pediatr Infect Dis J 2009 Jul; 28(7): 619–25PubMedCrossRefGoogle Scholar
  31. 31.
    Gallant JE, Winston JA, DeJesus E, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS 2008 Oct 18; 22(16): 2155–63PubMedCrossRefGoogle Scholar
  32. 32.
    Squires K, Pozniak AL, Pierone G, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med 2003 Sep 2; 139 (5 Pt 1): 313–20PubMedGoogle Scholar
  33. 33.
    Riordan A, Judd A, Boyd K, et al. Tenofovir use in human immunodeficiency virus-1-infected children in the United Kingdom and Ireland. Pediatr Infect Dis J 2009 Mar; 28(3): 204–9PubMedCrossRefGoogle Scholar
  34. 34.
    D’Amico G, Bazzi C. Urinary protein and enzyme excretion as markers of tubular damage. Curr Opin Nephrol Hypertens 2003 Nov; 12(6): 639–43PubMedCrossRefGoogle Scholar
  35. 35.
    Papaleo A, Warszawski J, Salomon R, et al. Increased beta-2 microglobulinuria in human immunodeficiency virus-1-infected children and adolescents treated with tenofovir. Pediatr Infect Dis J 2007 Oct; 26(10): 949–51PubMedCrossRefGoogle Scholar
  36. 36.
    Davey PG, Gosling P. Beta 2-microglobulin instability in pathological urine. Clin Chem 1982 Jun; 28(6): 1330–3PubMedGoogle Scholar
  37. 37.
    Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009 Mar 27; 23(6): 689–96PubMedCrossRefGoogle Scholar
  38. 38.
    Judd A, Boyd KL, Stöhr W, et al. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS 2010 Feb 20; 24(4): 525–34PubMedCrossRefGoogle Scholar
  39. 39.
    Guaraldi G, Roverato A, Giovanardi C, et al. Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study. J Antimicrob Chemother 2009 Feb; 63(2): 374–9PubMedCrossRefGoogle Scholar
  40. 40.
    Reid A, Stöhr W, Walker AS, et al. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis 2008 Apr 15; 46(8): 1271–81PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  • Alessandra Viganò
    • 1
  • Giorgio Bedogni
    • 2
  • Valeria Manfredini
    • 1
  • Vania Giacomet
    • 1
  • Chiara Cerini
    • 1
  • Francesca di Nello
    • 1
  • Francesca Penagini
    • 1
  • Cristiana Caprio
    • 1
  • Gian Vincenzo Zuccotti
    • 1
  1. 1.Department of Paediatrics“L. Sacco” Hospital, University of MilanMilanItaly
  2. 2.Clinical Epidemiology UnitLiver Research CentreBasovizzaItaly
  3. 3.Paediatric Clinic“L. Sacco” Hospital, University of MilanMilanItaly

Personalised recommendations